Menu

Source Legend
  • Human-provided

    Entered or confirmed by an authorized person.

  • Google

    Imported Google information.

  • Trial-derived

    Calculated or extracted directly from associated trial records.

  • AI-inferred

    A capability inferred from trial history.

  • AI-extracted

    An explicit statement extracted from an official source.

  • Public registry

    Information from a public registry.

  • Site record

    Information held in the site record.

Source: Site record. Velocity Clinical Research - Binghamton

Verified

Basic Information

Site Overview

Source: Human-provided.

Velocity Clinical Research – Binghamton is part of the Velocity Clinical Research integrated site network, providing comprehensive clinical trial services in New York State. The site conducts Phase I–IV clinical studies across a range of therapeutic areas, including vaccines, infectious diseases, cardiometabolic disorders, endocrinology, respiratory conditions, and general medicine. Its location in Binghamton allows access to a stable and diverse patient population, supporting efficient recruitment and strong participant retention. As a member of a centralized research network, the Binghamton site benefits from standardized operating procedures, regulatory expertise, and quality oversight systems that enhance study consistency and compliance. The facility supports pharmaceutical and biotechnology sponsors with study start-up, patient enrollment, data collection, and adherence to Good Clinical Practice (GCP) guidelines. With experienced investigators and trained clinical research…

Source: Trial-derived.
35Total Trials
Source: Trial-derived.
4Recruiting Trials
Source: Trial-derived.
8Active Trials
Source: Trial-derived.
25Completed Trials
Source: Trial-derived.
35Unique Conditions
Source: Trial-derived.
17Unique Sponsors

Affiliations

Conditions

Source: Trial-derived. Obesity (7)Source: Trial-derived. Overweight (4)Source: Trial-derived. SARS-CoV-2 (4)Source: Trial-derived. Influenza (3)Source: Trial-derived. Atherosclerotic Cardiovascular Disease (2)Source: Trial-derived. Cardiovascular Diseases (2)Source: Trial-derived. Diabetes Mellitus, Type 2 (2)Source: Trial-derived. Human (2)

Sponsors

Source: Trial-derived. ModernaTX, Inc. (9)Source: Trial-derived. Pfizer (5)Source: Trial-derived. Boehringer Ingelheim (4)Source: Trial-derived. Seqirus (4)Source: Trial-derived. Sanofi Pasteur, a Sanofi Company (3)Source: Trial-derived. Amgen (2)Source: Trial-derived. Eli Lilly and Company (2)Source: Trial-derived. Altesa Biosciences, Inc. (1)

Research Technology

Research technology inferred from trial participation

Source: AI-inferred. Telehealth study visits

Imaging & Diagnostics

Imaging and diagnostic capabilities inferred from trial participation

Source: AI-inferred. Electrocardiography (lead count not stated)

Laboratory & Biospecimens

Laboratory and biospecimen capabilities inferred from trial participation

Source: AI-inferred. Clinical laboratory testing
Source: AI-inferred. PCR / molecular
Source: AI-inferred. ELISA / immunoassay
Source: AI-inferred. Clinical microbiology culture
Source: AI-inferred. Sequencing / genomics

Accessibility & Parking

Accessibility Features

Source: Google. Wheelchair accessible entrance
Source: Google. Wheelchair accessible parking lot
Source: Google. Wheelchair accessible restroom

Additional Capabilities

Other capabilities inferred from trial participation

Source: AI-inferred. Blood glucose meter monitoring
Source: AI-inferred. Electronic participant diary (e-diary)
Source: AI-inferred. Electronic participant diary (ePRO) system
Source: AI-inferred. Electronic patient-reported outcome (eDiary) system
Source: AI-inferred. Hemagglutination inhibition (HAI) assay
Source: AI-inferred. Hemagglutination inhibition (HI) serology assay
Source: AI-inferred. Microneutralization assay
Source: AI-inferred. SARS-CoV-2 neutralising antibody titre assay